MEDICAL IMPLANTS WITH A COMBINATION OF COMPOUNDS

• US 20100074934A1
• Filed: 12/12/2007
• Published: 03/25/2010
• Est. Priority Date: 12/13/2006
• Status: Abandoned Application

• Current Assignee: Angiotech Pharmaceuticals Incorporated
• Original Assignee: Angiotech Pharmaceuticals Incorporated
• Inventors: Hunter, William L.
• Application Number:
  US12/518,962
• Publication Number:
  US 20100074934A1
• Time in Patent Office: Days
• US Class Current: 424/422
• CPC Class Codes: A61F 2/16 Intraocular lenses
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/45 Mixtures of two or more drugs, e.g. synergistic mixtures
• CPC Class Codes: A61L 27/00 Materials for grafts or prostheses or for coating grafts or prostheses dental prostheses A61C13/00; shape or structure of prostheses A61F2/00; use of preparations for artificial teeth A61K6/80; artificial kidneys A61M1/14
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 29/085 Macromolecular materials
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Implants are associated with a combination of paclitaxel or derivatives and dipyridamole or derivatives in order to inhibit fibrosis that may otherwise occur when the implant is placed within an animal. Exemplary implants include intravascular implants (e.g., coronary and peripheral vascular stents, catheters, balloons), non-vascular stents, pumps and sensors, vascular grafts, perivascular devices, implants for hemodialysis access, vena cava filters, implants for providing an anastomotic connection, electrical devices, intraocular implants, and soft tissue implants and fillers.

Claims

1. A device comprising a medical device, paclitaxel and dipyridamole, wherein paclitaxel is present in an amount ranging from about 0.01 to about 1.0 μ

g/mm² and dipyridamole is present in an amount ranging from about 0.05 to about 50 μ

g/mm² of medical device surface area.

2. The device of claim 1 wherein paclitaxel is present in an amount ranging from about 0.1 to about 0.6 μ

g/mm² and dipyridamole is present in an amount ranging from about 0.5 to about 5 μ

g/mm² of medical device surface area.

4. The device of claim 1 further comprising a polymer.

5. The device of claim 4 wherein the polymer is a non-biodegradable polymer.

6. The device of claim 4 wherein the polymer is a biodegradable polymer.

7. The device of claim 1 wherein the medical device is an intravascular device selected from a catheter, a balloon, and a vena cava filter.

8. The device of claim 1 wherein the medical device is selected from drug delivery pumps, sensors, non-vascular stents, vascular grafts, perivascular devices, implants for hemodialysis access, implants for providing an anastomotic connection, electrical devices, intraocular implants, and soft tissue implants and tissue fillers.

9. The device of claim 1 wherein the medical device is a coronary stent or a peripheral vascular stent.

10. The device of claim 1 wherein the paclitaxel has a biological effect, and the effect is greater in the presence of dipyridamole than in the absence of dipyridamole, and the biological effect is to minimize formation of neointimal hyperplasia.

3. A device comprising a medical device, paclitaxel and dipyridamole, wherein paclitaxel is present in an amount ranging from about 0.01 to about 1.0 μ

g/mm² and dipyridamole is present in an amount ranging from about 0.01 to about 1.0 μ

g/mm² of medical device surface area.

17. The device of claim 3 further comprising a polymer.

18. The device of claim 3 wherein the medical device is an intravascular device selected from a catheter, a balloon, and a vena cava filter.

19. The device of claim 3 wherein the medical device is selected from drug delivery pumps, sensors, non-vascular stents, vascular grafts, perivascular devices, implants for hemodialysis access, implants for providing an anastomotic connection, electrical devices, intraocular implants, and soft tissue implants and tissue fillers.

20. The device of claim 3 wherein the medical device is a coronary stent or a peripheral vascular stent.

21. The device of claim 3 wherein the paclitaxel has a biological effect, and the effect is greater in the presence of dipyridamole than in the absence of dipyridamole, and the biological effect is to minimize formation of neointimal hyperplasia.

11. A composition comprising paclitaxel and dipyridamole, wherein the weight ratio of dipyridamole to paclitaxel exceeds 0.06 to 1.0.

12. The composition of claim 11 wherein the paclitaxel has a biological effect, and the biological effect is greater in the presence of dipyridamole than in the absence of dipyridamole.

13. The composition of claim 11 comprising a combination of paclitaxel and dipyridamole, wherein the biological effect of the combination is greater than the sum of the effects of dipyridamole or paclitaxel acting alone.

14. The composition of claim 11 wherein the composition further comprises a polymer.

15. The composition of claim 14 wherein the polymer is a non-biodegradable polymer.

16. The composition of claim 14 wherein the polymer is a biodegradable polymer.